Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment - Slideshow

Corroborated by 2 sources from 2 publishers

ushealth2d ago

TL;DR

Reports differ across sources; according to seekingalpha.com, protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment - Slideshow.

Sources